About GenoPalate
GenoPalate is a Healthcare company based in Milwaukee (United States) founded in 2016 by Sherry Zhang. It operates as a personalized diet plans are offered based on genetic analysis. GenoPalate has raised $15.66 million across 9 funding rounds from investors including Gener8tor and BrightStar Wisconsin Foundation. Its chief executive is Sherry Zhang. Its website genopalate.com draws about 16 thousand monthly visits. Its focus areas include HealthTech, Fitness & Wellness Tech, Physical Fitness and Fitness and Diet Training Apps. Its competitors include Viome, Invitae, Color, Everlywell and Variant Bio and 5 more; 10 of its 10 listed competitors have raised funding.
Company details
GenoPalate was founded in 2016 in Milwaukee, United States, and operates in the personalized nutrition sector. DNA test kits are provided for sample collection, which are analyzed using a proprietary algorithm. Reports with diet and food recommendations are generated from the results. A customized toolkit containing nutritional information and advice is supplied to consumers for ongoing use.
- Headquarters Milwaukee, United States
- Founders Sherry Zhang
- SectorsHealthcare
- Website category Health · Nutrition Diets and Fitness
- Email••••••••
- Website genopalate.com
- Social LinkedIn X Facebook Instagram
- Total Equity Funding$15.66M (USD)
in 9 rounds
- Latest Funding Round$250K (USD), Series A
Feb 2026
- InvestorsGener8tor
& 1 more
Funding Insights of GenoPalate
GenoPalate has successfully raised a total of $15.66M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $250 thousand completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $15.66M
- Total Rounds 9
- Last Round Series A — $250,000
- First Round $100,000
(Jun 2017)
- Investors Count 2
All 9 funding rounds of GenoPalate with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in GenoPalate
GenoPalate has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Gener8tor and BrightStar Wisconsin Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Startups are accelerated via a 12-week program with funding support. | 2012 | gener8tor.com | Madison, United States | |
Capital is provided to Wisconsin entrepreneurs for job creation. | – | brightstarwi.org | Milwaukee, United States |
Investor details for GenoPalate
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GenoPalate
4 people are tracked at GenoPalate (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Sherry Zhang | Founder & CEO | Leadership |
Hector Guillen | VP of Research & Analytics | Leadership |
Hannah Pekarek | Product Manager | Team |
Frankie O’Brien | Clinical Dietitian | Team |
Complete people profiles for GenoPalate
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GenoPalate
3 dated milestones of GenoPalate across 10 years, from founding to its latest funding, stage changes and deals.
- Founded GenoPalate is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Series A, of $250K.
Competitors of GenoPalate
GenoPalate has 10 listed competitors in our database, 10 of them funded. They include Viome, Invitae, Color, Everlywell and Variant Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| everlywell.com | 2014 | Austin, United States | $330M | 614 | At-home health tests for biomarkers, nutrition, and hormone analysis. | |
| variantbio.com | 2018 | Brooklyn, United States | $127.74M | – | Personalized therapeutics are developed using genomic data for rare diseases. | |
| newtopia.com | 2008 | New York, United States | $13.1M | – | Health management platform is provided for employers and insurers. | |
| geneplanet.com | 2008 | Ljubljana, Slovenia | $34.02M | – | DNA-based personalized health and fitness recommendations are offered. | |
| insidetracker.com | 2009 | Cambridge, United States | $17.5M | 48 | Blood samples are analyzed for personalized health and wellness recommendations. | |
| counsyl.com | 2007 | San Francisco, United States | $112.89M | 503 | DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening | |
| digbihealth.com | 2018 | Mountain View, United States | $5.4M | – | Personalized healthcare is delivered through DNA and gut biome testing. |
Detailed competitors of GenoPalate
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GenoPalate
The website of GenoPalate (genopalate.com) receives about 16.5K visits a month and ranks #1,025,213 among all websites worldwide, #3,183 in Nutrition Diets and Fitness.
- Monthly visits16.5K
▼ 8.2% vs previous month
- Unique visitors7.9K
per month
- Global rank#1,025,213
among all websites
- Category rank#3,183
Health · Nutrition Diets and Fitness
- Bounce rate42%
- Pages per visit5.5
- Average visit3 min 18 sec
- DevicesDesktop 49% · Mobile 51%
Websites whose visitors overlap most with GenoPalate. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
zahlers.com | zahlers.com | 100% | – | #644,905 | – |
etherealgolddispensary.com | etherealgolddispensary.com | 99% | – | #698,750 | – |
kateminimalist.com | kateminimalist.com | 90% | – | #705,798 | – |
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as GenoPalate (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genopalate
Complete news archive for GenoPalate
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenoPalate
GenoPalate was founded in 2016 and raised its 1st funding round 1 year after it was founded.
GenoPalate is headquartered in Milwaukee, United States. It is registered at Milwaukee, Wisconsin, United States.
Sherry Zhang is the current CEO of GenoPalate. They have also founded this company.
GenoPalate is a funded company, having raised a total of $15.66M across 9 funding rounds to date. The company's 1st funding round was a Seed of $100K, raised on Jun 2017.
GenoPalate was founded in 2016 in Milwaukee, United States, and operates in the personalized nutrition sector. DNA test kits are provided for sample collection, which are analyzed using a proprietary algorithm. Reports with diet and food recommendations are generated from the results. A customized toolkit containing nutritional information and advice is supplied to consumers for ongoing use.
GenoPalate's top competitors include Viome, Variant Bio and Segterra (InsideTracker).
GenoPalate has 2 investors. Key investors include Gener8tor, and BrightStar Wisconsin Foundation.